1. Home
  2. RM vs CBIO Comparison

RM vs CBIO Comparison

Compare RM & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RM
  • CBIO
  • Stock Information
  • Founded
  • RM 1987
  • CBIO 2003
  • Country
  • RM United States
  • CBIO United States
  • Employees
  • RM N/A
  • CBIO N/A
  • Industry
  • RM Finance: Consumer Services
  • CBIO
  • Sector
  • RM Finance
  • CBIO
  • Exchange
  • RM Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • RM 414.8M
  • CBIO 308.0M
  • IPO Year
  • RM 2012
  • CBIO N/A
  • Fundamental
  • Price
  • RM $43.75
  • CBIO $14.29
  • Analyst Decision
  • RM Hold
  • CBIO Strong Buy
  • Analyst Count
  • RM 2
  • CBIO 5
  • Target Price
  • RM $30.00
  • CBIO $25.60
  • AVG Volume (30 Days)
  • RM 52.0K
  • CBIO 98.3K
  • Earning Date
  • RM 07-30-2025
  • CBIO 07-31-2025
  • Dividend Yield
  • RM 2.74%
  • CBIO N/A
  • EPS Growth
  • RM 35.30
  • CBIO N/A
  • EPS
  • RM 3.47
  • CBIO N/A
  • Revenue
  • RM $591,436,000.00
  • CBIO N/A
  • Revenue This Year
  • RM $16.20
  • CBIO N/A
  • Revenue Next Year
  • RM $7.43
  • CBIO N/A
  • P/E Ratio
  • RM $12.63
  • CBIO N/A
  • Revenue Growth
  • RM 7.19
  • CBIO N/A
  • 52 Week Low
  • RM $25.41
  • CBIO $10.83
  • 52 Week High
  • RM $43.91
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • RM 82.31
  • CBIO 52.92
  • Support Level
  • RM $36.88
  • CBIO $13.50
  • Resistance Level
  • RM $42.05
  • CBIO $16.00
  • Average True Range (ATR)
  • RM 1.29
  • CBIO 0.79
  • MACD
  • RM 0.49
  • CBIO 0.16
  • Stochastic Oscillator
  • RM 98.79
  • CBIO 39.68

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: